PuneetSCheemaMD

Oncology • Maplewood, MN

Physician

Join to view full profile

Dr. Cheema is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Cheema's full profile

Already have an account?

Office
1575 Beam Ave
Maplewood, MN 55109
Phone+1 651-232-7970

Education & Training

University of Arkansas for Medical SciencesFellowship, Hematology and Medical Oncology, 1999 - 2002
Rush University Medical CenterResidency, Internal Medicine, 1996 - 1999
Government Medical College AmritsarClass of 1995

Certifications & Licensure

AR State Medical License 1999 - 2026
FL State Medical License 2022 - 2025
MN State Medical License 2006 - 2025
TX State Medical License 2022 - 2025
WI State Medical License 2003 - 2025
IL State Medical License 1996 - 1999
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

239 citations
Immunomodulatory drug costimulates T cells via the B7-CD28 pathway.
Richard Leblanc, Teru Hideshima, Laurence Catley, Reshma Shringarpure, Renate Burger
Blood. 2004-03-01
109 citations
Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Ne...
Noah Kornblum, Fengmin Zhao, Judith Manola, Paula Klein, Bhuvaneswari Ramaswamy
Journal of Clinical Oncology. 2018-04-17
15 citations
A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408.
Andrew M. Evens, Fangxin Hong, Thomas M. Habermann, Ranjana H. Advani, Randy D. Gascoyne
Clinical Cancer Research. 2020-01-01

Abstracts/Posters

Combined Treatment with Lenalidomide and Epoetin Alfa Leads to Durable Responses in Patients with Epo-Refractory, Lower Risk Non-Deletion 5q [Del(5q)] MDS: Final Resul...
Puneet S. Cheema, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019